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Abstract 
The Ninth Annual Conference of “Anticancer Innovative Therapy”, organized by Fondazione IRCCS 
Istituto Nazionale dei Tumori di Milano (Fondazione IRCCS INT) and hosted by Hotel Michelangelo, 
was held in Milan on 25 January 2019. Cutting-edge science was presented in two main scientific 
sessions: i) pre-clinical evidences and new targets, and ii) clinical translation. The Keynote lecture 
entitled “Cancer stem cells (CSCs): metabolic strategies for their identification and eradication” 
presented by M. Lisanti, was one of the highlights of the conference.  
One key concept of the meeting was how the continuous advances in our knowledge about 
molecular mechanisms in various fields of research (cancer metabolism reprogramming, 
epigenetic regulation, transformation/invasiveness, and immunology, among others) are driving 
cancer research towards more effective personalized antineoplastic strategies. Specifically, recent 
preclinical data on the following topics were discussed: 1. Polycomb group proteins in cancer; 2. A 
d16HER2 splice variant is a flag of HER2 addiction across HER2-positive cancers; 3. Studying 
chromatin as a nexus between translational and basic research; 4. Metabolomic analysis in cancer 
patients; 5. CDK4-6 cyclin inhibitors: clinical activity and future perspectives as immunotherapy 









eradication. In terms of clinical translation, several novel approaches were presented: 1. 
Developing CAR-T cell therapies: an update of preclinical and clinical development at University of 
North Carolina; 2. Vγ9Vδ2 T-cell activation and immune suppression in multiple myeloma; 3. 
Predictive biomarkers for real-world immunotherapy: the cancer immunogram model in the 
clinical arena; and 4. Mechanisms of resistance to immune checkpoint blockade in solid tumors. 
Overall, the pre-clinical and clinical findings presented could pave the way to identify novel 
actionable therapeutic targets to significantly enhance the care of persons with cancer.    
 
1. Introduction 
The Ninth Annual Conference on “Anticancer Innovative therapy”, organized by Fondazione IRCCS 
Istituto Nazionale dei Tumori of Milano (Fondazione IRCCS INT), was held in Milan (Italy) on the 25 
January 2019. Leading international experts in the fields of immuno-oncology, epigenetic 
mechanisms controlling tumor proliferation/survival, cancer cell signaling and dysregulated cancer 
metabolism provided new insights that aim to define more effective therapeutic opportunities.  
The increasing knowledge about the molecular mechanisms responsible for neoplastic 
transformation/invasiveness, the role of the epigenetic landscape in defining both chromatin 
architecture and gene expression profile in cancer cells, the immunological mechanisms regulating 
tumor-host interaction and the effects of metabolic reprogramming in cancer cell biology will 
allow researchers and clinicians to identify and apply new, more effective anti-cancer therapeutic 
options.  
To date, immuno-biotherapy is a continuously evolving treatment modality integrated into the 
treatment algorithms of several different oncotypes. Furthermore, elucidating the resistance 
mechanisms against anti-tumor therapies and then exploiting novel knowledge of cancer 
vulnerabilities will ultimately improve cancer therapy and patient survival. 
Session I of the conference comprised the following topics: 1) Polycomb group proteins in cancer; 
2) d16HER2 splice variant as a flag of HER2 addiction across HER2-positive cancers; 3) the role of 
chromatin as nexus between translational and basic research; 4) metabolomic analysis in cancer 
patients; 5) CDK4-6 cyclin inhibitors: clinical activity and future perspectives as immunotherapy 
adjuvant. Moreover, during this session, the invited keynote lecture was presented by Michael 
Lisanti who illustrated new metabolic strategies for the identification and eradication of Cancer 
Stem Cells (CSCs) in breast cancer. Session II included: 1) the development of CAR-T cell therapies: 









activation and immune suppression in multiple myeloma; 3) predictive biomarkers for real-world 
immunotherapy: the cancer immunogram model in the clinical arena; and 4) mechanisms of 
resistance to immune checkpoint blockade in solid tumors.  
Finally, two selected abstracts from young researchers were presented on the following topics: 1) 
BCL6 as a novel target of triple negative breast cancer stem cells; 2) the capacity of coated cationic 
liposomes entrapping mir-660 to inhibit tumor growth in patient-derived xenograft lung cancer 
models. Overall, the latest achievements in the most innovative areas of cancer research were 
presented and critically discussed.  
2. SESSION I: Preclinical evidences and new targets 
2.1 Polycomb group proteins in cancer    
Adrian Bracken (Trinity College Dublin, Ireland) offered a wide overview on chromatin modifier 
proteins with a focus on Polycomb group proteins (PCG). In particular, the process through which 
transcription factors have access to DNA is regulated by a set of chromatin-remodeling machines 
that alter nucleosome position and structure. The orchestrated regulation of chromatin assembly 
is critical for gene expression, as it determines its accessibility to specific transcription factors in a 
precise, sequential order. Chromatin remodelers are ATP-hydrolyzing machines specialized in 
restructuring, mobilizing or ejecting nucleosomes, which allow exposure of the DNA in the 
chromatin to be regulated. As cancer is a disease that can be driven by epigenetic changes, it is not 
surprising that chromatin remodelers are among the most frequently mutated enzymes. PCG are 
often in multi-protein complex with different functions in the economy of chromatin metabolism. 
In particular, the SET domain of the catalytic subunit EZH2 is in charge of methyl group deposition 
at lysine 27 of histone H3 (to produce H3K27me3). It requires the presence of 2 additional 
proteins, embryonic ectoderm development (EED) and Suppressor of Zeste 12 (SUZ12). 
Deregulated H3K27me3 levels have been demonstrated in a variety of human cancers (Morin, 
Mendez-Lago et al. 2011, Cromer, Starker et al. 2012, Hodis, Watson et al. 2012).  
A decade ago, acquired EZH2 mutations were identified in lymphoma and myeloid neoplasms. In 
lymphoma, a heterozygous missense mutation at amino acid Y641, within the SET domain, was 
identified with high-throughput transcriptome sequencing. In myeloid neoplasm, mutations have 
been described in poor prognosis myelodysplasia–myeloproliferative neoplasms, myelofibrosis, 
and various subtypes of myelodysplastic syndromes (Ernst, Chase et al. 2010, Nikoloski, 
Langemeijer et al. 2010). The therapeutic modulation of epigenetic marks has led to 









demethylating agents azacitidine and decitabine for myelodysplastic syndrome (Fenaux, Mufti et 
al. 2009, Fenaux, Mufti et al. 2010) and the HDAC inhibitor suberoylanilide hydroxamic acid 
(vorinostat) for cutaneous T-cell lymphoma (Olsen, Kim et al. 2007). EZH2 inhibition or depletion 
has been reported to be effective for treating different type of cancers, and several selective 
inhibitors have been designed to this aim. In particular, GSK126, a selective inhibitor of EZH2, is 
now in clinical trial. However, in the attempt to consider EZH2 inhibitors in clinical practice, 
identification of secondary EZH2 mutations that cooperate to confer resistance to these inhibitors 
must be taken into account, as the possibility exists that acquired resistance to EZH2 inhibitors 
could occur also in patients (Baker, Nerle et al. 2015, Gibaja, Shen et al. 2016). Based on this broad 
picture, it is clear that a deep understanding of epigenetic mechanisms that govern basic cellular 
functions is of fundamental importance for developing more specific, targeted and effective 
therapies. 
 
2.2 The d16HER2 splice variant is a flag of HER2 addiction across HER2-positive cancers  
Serenella M. Pupa (Department of Research, Fondazione IRCCS INT, Milan, Italy) provided the 
audience with the latest updates on the breast cancer (BC) subtype characterized by the 
amplification/overexpression of the HER2 receptor (making up 15-20% of BC) (Prat and Perou 
2011). In particular, her talk addressed the pathobiological roles displayed by one of the HER2 
splice variant, denominated d16HER2, in HER2-positive (HER2+) BC. Although innovative 
therapeutic options that specifically target HER2 have been introduced and have revolutionized 
HER2+ disease outcome, about 50% of patients with HER2+ BC are intrinsically resistant or have 
acquired resistance to these new biodrugs (Loibl and Gianni 2017), implying the need to increase 
our knowledge about HER2 biology. Evidence suggests that the co-existence of the full-length, 
wild-type (WT) HER2 oncoprotein (WTHER2) together with altered forms of HER2, such as 
carboxy-terminal–truncated fragments (Zagozdzon, Gallagher et al. 2011), activating mutations 
(Weigelt and Reis-Filho 2013), or splice variants (Jackson, Browell et al. 2013), significantly 
increases the heterogeneity of HER2+ disease, affecting its biology, clinical course, and treatment 
response (Chen and Weiss 2015). In this context, pre-clinical studies performed in proper 
transgenic (tg) mouse models provided the first direct evidence that the mammary-specific 
expression of rodent (HER2/neu) as well as distinct forms of human HER2 genes induced 
spontaneous tumors development only when coupled with in-frame activating deletions or 









Schade et al. 2007). In particular, previously reported findings have clearly demonstrated that the 
imbalance of cysteines plays a crucial role in regulating the catalytic/oncogenic activity of HER2 
(Chan, Muller et al. 1999), by activating the receptor as a consequence of constitutive 
homodimerization through the formation of stable intermolecular disulfide bridges (Chan, Muller 
et al. 1999, Siegel, Ryan et al. 1999). Along with other groups, Pupa and colleagues reported that 
HER2+ BC, together with WTHER2, constitutively express the d16HER2 splice variant, structurally 
characterized by the in-frame deletion of exon 16 in the juxtamembrane region of HER2/ECD 
fragment. This deletion promotes the elimination of two crucial cysteines and, in turn, the 
formation of constitutively-activated d16HER2 homodimers (pd16HER2D) on the tumor cell 
surface (Kwong and Hung 1998, Siegel, Ryan et al. 1999, Castiglioni, Tagliabue et al. 2006, Mitra, 
Brumlik et al. 2009). Generation and then comparison of specific transgenic cell lines for the 
human d16HER2 variant (Marchini, Gabrielli et al. 2011) and the WTHER2 isoform (Finkle, Quan et 
al. 2004) revealed a significantly shorter tumor latency period and a higher tumor incidence in the 
d16HER2 line, clearly pointing at the candidacy of d16HER2 as the oncogenic “driver” isoform of 
the HER2 gene (Castagnoli, Iezzi et al. 2014). Additionally, therapeutic experiments performed in 
parallel in the two transgenic mouse lines with the humanized monoclonal antibody trastuzumab 
(T), the gold standard care for HER2+ tumors, provided evidence of a significantly higher 
susceptibility of lines containing d16HER2 than those with WTHER2 to the biodrug (Castagnoli, 
Iezzi et al. 2014). In the same study, novel important insights into the functional relationship 
between the splice variant d16HER2D and activated SRC (pSRC) were provided both in pre-clinical 
and clinical settings, allowing us to consider intratumor pSRC expression as a surrogate marker of 
d16HER2D expression in HER2+ BC (Castagnoli, Iezzi et al. 2014). Further, a Gene Set Enrichment 
Analysis (GSEA) of the whole transcriptome of human HER2+ BC specimens stratified for high 
versus low levels of pSRC expression, the intra-tumor mirror of pd16HER2D expression, showed 
significantly enrichment in hypoxia, tumor metastasis, and cell motility gene pathways only in 
high-expressing pSRC/d16HER2 BC. This strongly suggests that d16HER2 is a key molecule involved 
in HER2-driven aggressiveness and stemness.  Accordingly, in recent studies, Pupa and colleagues 
demonstrated that the enrichment of d16HER2 expression versus its wild-type counterpart 
(WTHER2) significantly influences HER2+ BC-initiating cells (BCIC) properties (Castagnoli, Ghedini 
et al. 2017). Further, her team provided evidence of a significant up-regulation of glucose 
metabolism in HER2+ BC models enriched in the pd16HER2/pSRC signaling axis versus those 








high pd16HER2/pSRC–expressing BC (Castagnoli, Iorio et al. 2019). Altogether, the findings 
indicate that d16HER2 expression/activation strongly reflects the status of HER2 oncogenic 
signaling dependence, which has been defined as a “HER2 addiction” (Alajati, Sausgruber et al. 
2013, Turpin, Ling et al. 2016, Castagnoli, Iorio et al. 2019) and represents a novel and potentially 
clinically useful biomarker (Castagnoli, Ladomery et al. 2019). Lastly, to overcome the difficulty of 
intra-tumor detection of the d16HER2 isoform at the protein level, Pupa and colleagues recently 
established a novel mRNA bright-field in situ hybridization (ISH) technique to score and 
discriminate intra-tumor expression of d16HER2 mRNA from the WTHER2 mRNA. Applied to 
HER2+ BC and gastrointestinal (GC) malignancies, this technique allowed them to demonstrate the 
existence of outliers with high d16HER2 mRNA scores that only occurred in HER2+ GC (Volpi, 
Pietrantonio et al. 2019). Of note, a significant association between having a high d16HER2 score 
and prolonged progression free survival was found also in HER2+ GC treated with T, strongly 
suggesting that d16HER2 could be clinically investigated as a marker of T susceptibility in several 
HER2-driven cancers (Castagnoli, Ladomery et al. 2019). 
 
2.3 Studying chromatin as a nexus between translational and basic research   
The highly-regulated packaging of the genome into chromatin represents the basis of epigenetic 
regulation, and alterations at the epigenetic level contribute to cancer development and 
progression. Marcus Buschbeck (Josep Carreras Leukaemia Research Institute, Campus ICO, 
Germans Trias I Pujol, UAB, Barcelona, Spain) illustrated data obtained in his lab aimed at 
understanding chromatin regulation at the mechanistic level. Focusing on the age-related 
hematopoietic stem cell defect myelodysplatic syndrome (MDS) and its progression to acute 
myeloid leukemia (AML), the speaker showed that RING1A, the catalytically active subunit of the 
Polycomb repressive complex 1 (PRC1), is overexpressed in high-risk patients with MDS. This 
highlights the key role of this epigenetic regulator in the pathogenesis of MDS. However, RING1A 
pharmacological inhibition affects the stem cell compartment in both MDS patients and healthy 
donors, hampering its clinical applicability (Palau, Garz et al. 2017). The Buschbeck group applies 
genetic screening methods (Fellmann, Hoffmann et al. 2013) and cell culture models to identify 
chromatin regulators able to increase the response to the nucleoside-analogue azacitidine. 
Although azacitidine is the current treatment of choice for high-risk patients with MDS who are 
not eligible for allogenic hematopoietic stem cell transplantation, the success is limited by the 









presented his most recent promising results showing that using targeted small molecule inhibitors 
to inhibit histone-modifying enzymes can increase the cytotoxic response of AML cells to 
azacitidine. If further validated in vivo, the use of such inhibitors would provide the rationale for 
the development of a combinatorial treatment. His lab is also actively involved in understanding 
the function and regulation of a group of macroH2A histone variants in embryonic development 
and cancer. The regulated deposition of histone variants into specific chromatin regions can 
directly influence gene transcription due to their ability to alter nucleosome stability and 
chromatin organization (Buschbeck and Hake 2017). Unlike other histones, the structure of 
macroH2As is composed of two C-terminal domains, an unstructured linker that contributes to 
higher-order chromatin architecture (Douet, Corujo et al. 2017, Kozlowski, Corujo et al. 2018), and 
a globular macrodomain that is a binding module for the NAD+–derived metabolite ADP ribose 
(Posavec, Timinszky et al. 2013). As the isoform macroH2A1.1 is also able to bind ADP-ribosylated 
proteins, it consequently binds and inhibits the stress sensor PARP1 (Hurtado-Bages, Guberovic et 
al. 2018). Thereby, macroH2A1.1 can limit PARP1-dependent chromatin remodeling after DNA 
damage (Kozlowski, Corujo et al. 2018). As PARP1 is the major NAD+ consuming enzyme, inhibition 
by macroH2A1.1 impacts global NAD+ metabolism (Posavec Marjanovic, Hurtado-Bages et al. 
2017). In this context, Buschbeck and colleagues are investigating whether the function of the 
linker in 3D chromatin architecture and of the macrodomain in metabolite-binding are coupled. 
This would further define the role of macroH2A histone variants in connecting metabolic cellular 
clues to heterochromatin architecture.  
 
2.4 Metabolomic analysis in cancer patients  
Andre Wegner (Technische Universität [TU] Braunschweig, Germany) exemplified the potential 
of the metabolomic analysis in cancer research. Metabolic reprogramming is known to be an 
important hallmark of cancer cells (Hanahan and Weinberg 2011). It is often the result of 
alterations in the upstream compartments (genome, transcriptome, proteome) and directly 
affects the phenotype of a biological system (Cantor and Sabatini 2012). Uncovering the 
mechanisms underpinning the metabolic alterations opens novel therapeutic opportunities. In 
particular, analyzing changes in the total pool of metabolites, i.e. metabolomics, can be exploited 
to discover novel disease biomarkers, although it only provides a static picture about metabolism. 
In contrast, analyzing metabolic fluxes can better elucidate disease mechanisms and identify 









as metabolic substrates in the context of 13C-metabolic flux analysis (13C-MFA) is a powerful tool 
for following specific metabolites production and consumption (Lane, Fan et al. 2009). The mass 
isotopomer distribution (MID) can then be evaluated by mass spectrometry (MS) for each 
metabolite with a 13C-label incorporated, and the labeling patterns are analyzed to trace specific 
pathways and calculate metabolic fluxes.  
Dr. Wegner also presented data on lung cancer cell metabolism. In particular, they evaluated the 
metabolism of the lung cancer cell line A549 by incubating cells with [U-13C]glutamine or [1,2-
13C]glucose, and subsequently analyzing the MID by gas chromatography MS (GC/MS). 
Surprisingly, the metabolite N-acetyl-aspartic acid (NAA), known to be the most abundant amino 
acid in the brain, was produced by these lung cancer cells, and synthesized by the N-
acetyltransferase 8-like (NAT8L) enzyme, as confirmed by silencing experiments. Even though the 
NAA functional role in the context of lung cancer remains unclear, Wegner and collaborators 
showed that loss of NAA by NAT8L silencing reduced cell proliferation (Weindl, Cordes et al. 2016). 
NAT8L knockout also had consequences at the metabolic level, such as decreased levels of 
glycerol-3-phosphate, while NAA overexpression induced increases in aspartic acid and glycerol-3-
phosphate. Strikingly, NAA did not show 13C label incorporation when permeabilized cells 
(Nonnenmacher, Palorini et al. 2017) were cultured with either pyruvate or glutamine that had 
been 13C-labelled, suggesting that this metabolite is not produced from pyruvate or glutamine in 
the mitochondria. Further experiments are needed to better elucidate the role of NAA in lung 
cancer.  
 
2.5 CDK4-6 cyclin inhibitors: clinical activity and future perspectives as immunotherapy adjuvant  
Serena Di Cosimo (Department of Applied Research and Technological Development, 
Fondazione IRCCS INT, Milan, Italy) addressed the key topic of CDK4/6 inhibitors as modulators of 
immune response for anti-tumor therapies. In particular, and according to the recent literature on 
this subject, Dr. Di Cosimo reported that CDK4/6 inhibitors are effective in treating advanced 
hormone receptor–positive, HER2-negative metastatic BC. Combined with endocrine therapy (i.e. 
the aromatase inhibitor letrozole and the selective estrogen receptor degrader fulvestrant), the 
CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib have substantially improved progression-
free survival and response rates when used both as the first and advanced lines of treatment for 
this category of patients. The drugs work by selectively turning off overactive CDK4 and CDK6, 







well-known cell cycle progression checkpoint. As a result, the division cycle in cancer cells is 
halted, preventing them from proliferating.  
Recent work has revealed that the antitumor activity of CDK4/6 inhibitors not only rely on blocking 
cell division, but also on unleashing the immune system to attack the cancer cells. Different 
preclinical studies using animal models of BC found that the CDK4/6 inhibitors (i) induce secretion 
of IFN gamma, which in turn enhances the presentation of tumor antigens to cytotoxic T cells; (ii) 
reduce the population of immune-suppressing T-regulatory cells in the tumor microenvironment; 
and (iii) increase the antitumor activity of immune checkpoint–blocking antibodies (Figure 1) 
(Goel, DeCristo et al. 2017, Deng, Wang et al. 2018, Schaer, Beckmann et al. 2018). 
INSERT Figure 1 
Even though the CDK4/6 inhibitors have been shown to be most effective for metastatic luminal 
BC, and are only approved for wide use in that type of cancer, evidence shows promising activity 
also in other forms of cancer, including liposarcoma, non–small-cell lung cancer, mantle cell 
lymphoma, melanoma, and glioblastoma. Hence, these new findings significantly expand the use 
of CDK4/6 inhibitors for treatment of other cancers based on an immune-mediated effect. Finally, 
two studies are currently evaluating CDK4/6 inhibitors and their potential to modulate immune 
response in women with metastatic and locally advanced BC, who should receive endocrine 
therapy in combination with immune checkpoint–blocking antibodies pembrolizumab or 
avelumab, respectively.  
 
2.6 Cancer stem cells (CSCs): metabolic strategies for their identification and eradication  
Michael Lisanti (University of Salford, UK) presented the keynote lecture on new possible 
approaches to counteract CSCs. Mitochondria are known to be the energetic hub of a cell, and 
their function and homeostasis is fundamental for cell survival. The “reverse Warburg effect” 
theory states that cancer cell mitochondria oxidatively metabolize nutrients (i.e. lactate, ketones) 
provided by adjacent stromal cells that are undergoing aerobic glycolysis (Pavlides, Whitaker-
Menezes et al. 2009), the so-called “two-compartment tumor metabolism” model (Sotgia, 
Whitaker-Menezes et al. 2012). This metabolic coupling supports mitochondrial ATP production 
via oxidative phosphorylation (OXPHOS) in the anabolic cancer cells, promoting a stemness 
phenotype, metastatic potential, and tumor growth (Martinez-Outschoorn, Peiris-Pages et al. 
2017). Given the key role of mitochondrial metabolism in CSC maintenance and drug resistance 









counteract CSC via targeting mitochondria. They first demonstrated that mitochondrial proteins 
(both metabolic enzymes as well as mitochondrial biogenesis-related proteins) are upregulated in 
mammospheres derived from the MCF7 and T47D BC cell lines (Lamb, Harrison et al. 2014). The 
pivotal involvement of mitochondria in supporting a stemness phenotype was further confirmed 
by the detrimental effect of oligomycin A treatment (a known inhibitor of the mitochondrial ATP 
synthase) on the mammosphere forming efficiency (Lamb, Harrison et al. 2014). Mitochondrial 
metabolism could therefore be exploited to eradicate CSCs in various tumor types. To this aim, 
Lisanti and colleagues demonstrated that mitochondrial mass could be used as a metabolic 
biomarker for stem-like cancer cells. In particular, cells with high mitochondrial mass (“mito-high”, 
as detected by the MitoTracker deep red dye) more closely resembled the CSC features, such as 
having higher ALDH activity, mammosphere formation capacity, tumorigenic potential, and a 
chemo-resistant phenotype (Farnie, Sotgia et al. 2015). The possibility to isolate the most therapy-
resistant components of a tumor represents a powerful tool to investigate drug sensitivity in the 
context of personalized cancer treatment (Figure 2).  
INSERT FIGURE 2 
Different classes of FDA-approved antibiotics are known to inhibit mitochondrial biogenesis as an 
“off-target” effect. Lisanti and collaborators have suggested re-purposing antibiotics (i.e. 
doxycycline) for CSC eradication as a novel cost-effective cancer treatment approach of broad 
applicability (Lamb, Ozsvari et al. 2015). Doxycycline treatment has indeed shown the capacity to 
reduce the mammosphere-forming efficiency of BC cell lines in vitro, as well as of CSCs derived 
from metastatic BC patients (Lamb, Ozsvari et al. 2015). Interestingly, doxycycline has also shown 
effects on the MCF7 cell metabolism; in particular, it was able to reduce levels of both OXPHOS 
and glycolysis, transforming the highly energetic cells into quiescent ones.  
In the clinical setting, doxycycline treatment has previously shown promising results in MALT 
lymphoma patients (Ferreri, Ponzoni et al. 2006). Moreover, a phase II clinical trial testing the 
combination of doxycycline and chemotherapy has been approved for early BC patients at the Pisa 
University Hospital (Italy). Preliminary results showed reduced CD44 and ALDH1 expression in the 
BC tissue after doxycycline administration. With the idea to overcome a possible development of 
antibiotic resistance, Lisanti and collaborators explored several treatment combinations with 
metabolic inhibitors, aimed at exploiting the metabolic features and vulnerability acquired during 
adaptation to treatments. For instance, BC cells resistant to doxycycline are characterized by a 









in a synthetic lethal approach able to eradicate these CSCs (De Francesco, Bonuccelli et al. 2017). 
Recent data from the Lisanti group revealed the existence of a subset of CSCs defined “energetic 
CSCs”, characterized by higher metabolic activity (higher mitochondrial OXPHOS), hyper-
proliferation, enrichment in stem cell features (ALDH activity, sphere-forming efficiency, 
mitochondrial mass), and dependence on a 3D micro-environment. Given these peculiar 
characteristics, the “energetic CSC” subpopulation can be pharmacologically targeted with 
OXPHOS inhibitors (i.e. DPI) and CDK4/6 inhibitors (i.e. ribociclib) (Fiorillo, Sotgia et al. 2018). 
Overall, these novel approaches targeting CSC mitochondria with repurposed drugs pave the way 
to more affordable as well as highly effective and durable treatments.  
 
3. SESSION II: Clinical translation 
3.1 Developing CAR-T cell therapies: an update of preclinical and clinical development at the 
University of North Carolina  
Gianpietro Dotti (University of North Carolina, Chapel Hill, USA) presented his most recent data 
in CAR-T cell therapy. The engineering of chimeric antigen receptors (CARs) in T-cells has fuelled 
the rapid generation of tumor-specific cells, increasing the clinical applicability of adoptively–
transferred cell therapies. Targeting CD19 via CAR-T cells is highly effective in B-cell malignancies 
(Hay and Turtle 2017). A similar approach was developed to treat Hodgkin’s lymphoma (HL) by 
targeting CD30. Treatment with CAR-modified T-cells targeting CD30 (CD30.CAR-Ts) without 
lymphodepletion was found to be safe with preliminary efficacy in patients with 
relapsed/refractory (r/r) CD30+ lymphomas (Figure 3) (Ramos, Ballard et al. 2017). Prof. Dotti 
reported the results of a phase 1b/2 trial of CD30.CAR-Ts infused after lymphodepletion with 
either bendamustine (benda) alone, or a combination of benda and fludarabine (flu), in 24 
patients with r/r CD30+ Hodgkin (HL) and non-Hodgkin lymphoma (NHL) who had undergone a 
median of 7.5 prior lines of therapy. They observed no dose-limiting toxicities, no neurological 
toxicity, and mild and self-limiting cytokine release syndrome. At the 6-week assessment, 10 
patients in the benda/flu cohort had CR (53%), 2 had partial response (11%), 2 had stable disease 
(11%), and 5 had progressive disease (26%, including all 3 patients treated at DL1). The addition of 
flu to lymphodepletion also improved T-cell expansion and persistence. The trial showed that 
autologous CD30.CAR-T cells are extremely well tolerated and can have significant clinical activity 
in heavily pre-treated patients with r/r HL when the lymphodepleting conditioning regimen 








remain susceptible at the tumor site to the PD-L1 inhibition, suggesting that the next step to 
further enhance efficacy will require a combination of CD30.CAR-T cells and checkpoint blockades. 
INSERT FIGURE 3 
3.2 Vγ9Vδ2 T-cell activation and immune suppression in multiple myeloma  
Massimo Massaia (Department of Molecular Biotechnology and Health Sciences, Turin, Italy) 
discussed the main issues in the application of Vγ9Vδ2 T-cell–based immunotherapy in the context 
of multiple myeloma (MM). Vγ9Vδ2 T-cells are considered as non-conventional, bearing the 
characteristics of both adaptive and innate immunity. In particular, these cells are able to react 
against malignant B-cells, and therefore against malignant myeloma cells, and are activated by 
self-phosphoantigens (pAgs), including the phosphorylated metabolites produced in the 
mevalonate pathway (i.e. isopentenyl pyrophosphate, IPP) (Castella, Vitale et al. 2011). Given the 
capacity of zoledronic acid (ZA) to inhibit the mevalonate pathway, this could be exploited to test 
Vγ9Vδ2 T-cells reactivity. In fact, ZA treatment on antigen-presenting cells (APC) induces the 
intracellular accumulation and extracellular release of IPP, which is detected by Vγ9Vδ2 T-cells. 
However, Vγ9Vδ2 T-cells derived from the bone marrow of patients with MM or monoclonal 
gammopathy of undetermined significance (MGUS) are characterized by a defective reactivity to 
IPP and are therefore considered anergic. These cells are also PD-1+, in line with the 
immunosuppressive TME of MM patients. Interestingly, single PD-1 blockade induced the 
expression of multiple immune checkpoint molecules (ICPs), such as PD-1, TIM-3, and LAG-3, on 
the MM BM-infiltrating Vγ9Vδ2 T-cells (thereby defined a “super-anergic” state). These results 
suggest that a more aggressive approach of combining multiple anti-ICP antibodies is the only way 
to effectively overcome TME immunosuppression. However, the clinical application of this 
approach is limited by the huge costs and the high toxicities induced by these drugs. Further 
studies to understand the mechanisms underpinning ICP expression are necessary to be able to 
rescue Vγ9Vδ2 T-cells from their immune dysfunction (Castella, Melaccio et al. 2018).  
 
3.3 Predictive biomarkers for real-world immunotherapy: the cancer immunogram model in the 
clinical arena 
Giancarlo Pruneri (Fondazione IRCCS INT, Milan, Italy) illustrated the existing predictive 
biomarkers in the context of immunotherapy. Despite having highly promising therapeutic 
potential, immunotherapy results in clinical benefit for only a small portion of patients (8–10%). It 









infiltrating lymphocytes (TILs) can be considered a read-out of tumor immunogenicity. Indeed, a 
higher TIL infiltration is detected in the basal-like and HER2+ subtypes of BC (Luen, Virassamy et al. 
2016). Moreover, TIL detection has shown prognostic value of response to therapy in TNBC 
patients in the adjuvant setting (Pruneri, Gray et al. 2016). Recent clinical evidence demonstrate 
that quantification of stromal TILs in BC patients has a subtype-dependent prognostic role and can 
be considered as a reproducible biomarker (Loi, Drubay et al. 2019). Interestingly, having a 
percentage of stromal TILs of >20% in node-negative early-stage TNBC patients correlates with a 
good prognosis (Loi, Drubay et al. 2019).  
Tumors with high prevalence of somatic mutations (>150 mutations) are prone to neoantigen 
formation (Schumacher and Schreiber 2015), and as such are more immunogenic and show 
survival benefits after immune checkpoint blockade. The tumor mutational burden (TMB) is 
therefore considered a promising biomarker, and its detection has been included in clinical trials. 
For instance, a high TMB demonstrated improved efficacy of nivolumab or nivolumab/ipilimumab 
treatment in small-cell lung cancer (Hellmann, Callahan et al. 2018) and NSCLC (Hellmann, 
Nathanson et al. 2018). Interestingly, the efficacy was further improved (higher complete/partial 
response rate) in patients with both high TMB and PD-L1 positivity (Hellmann, Nathanson et al. 
2018), suggesting that the combination of two or more biomarkers could be a more reliable 
approach to stratify patients.  
However, standardized gene panels are needed to introduce TMB detection into the clinical 
routine. The Oncomine Tumor Mutation Load Assay (ThermoFisher) represents a multi-biomarker 
next-generation sequencing-based assay useful to profile clinical samples and is able to detect 409 
cancer-driver genes. However, Dr. Pruneri stressed that the biggest limitation of this approach is 
technical: FFPE processing, and in particular the formalin fixation step, is able to induce somatic 
mutations itself, affecting the interpretation of results. Further optimizations are therefore 
needed in order to consider TMB as a reliable biomarker.  
 
3.4 Mechanisms of resistance to immune checkpoint blockade in solid tumors 
Andrea Anichini (Fondazione IRCCS INT, Milan, Italy) addressed the important question about 
resistance to immune checkpoint blockade (ICB) in the context of solid tumors. Clinical efficacy of 
immunotherapy by ICB is often hampered by a number of mechanisms of intrinsic and acquired 
resistance (Galluzzi, Chan et al. 2018). Several of these mechanisms act by preventing 








recognition and elimination, even when tumor-specific T-cells are present. Dr. Anichini 
investigated these mechanisms by integrating the assessment of selected immune-related gene 
signatures with the analysis of immune contexture and of HLA expression at the tumor site. A key 
aspect of the approach was the comparison of pre- and post-therapy lesions from melanoma 
patients treated with anti-CTLA-4 (Jerby-Arnon, Shah et al. 2018) and from bladder cancer patients 
treated with anti-PD-1 antibody (Necchi, Anichini et al. 2018). In the melanoma patients who did 
not respond to treatment, the post-therapy lesions showed significant reduction of expression of 
genes involved in T-cell differentiation/function (LCK, GZMB, TBX21), T-cell recruitment (CXCL9, 
CXCL10), IFN-, and STING pathway functions, as well as HLA class I antigen processing and 
presentation (NLRC5, TAP1, TAP2, PSMB9) (as compared to pre-therapy lesion). This indicates that 
multiple mechanisms of resistance are acting at the same time in the same lesion. Reduced 
expression of HLA class I molecules on neoplastic cells, as well as T-cell exclusion from the tumor 
tissue, were confirmed by immunohistochemistry in pre- and post-therapy lesions from several 
non-responding patients (Jerby-Arnon, Shah et al. 2018). In bladder cancer patients enrolled in a 
neoadjuvant trial with anti-PD-1, immune-related gene signature analysis was carried out by 
comparing pre-therapy biopsies with the post-therapy surgical sample. In non-responding 
patients, this analysis showed that the therapeutic antibody was effective in the activation of anti-
tumor immunity (increased expression of T-cell–related genes, T-cell–recruiting chemokine genes, 
and IFN-–related genes in post-therapy surgical samples). However, these positive effects 
coexisted with strong promotion of several mechanisms of resistance such as: I) upregulation of 
inhibitory receptors and ligands genes, II) promotion of IDO1 expression, and III) boost in 
expression of genes coding for chemokines that recruit myeloid suppressor cells (Necchi, Anichini 
et al. 2018). Taken together, these results suggest that resistance to immune checkpoint blockade 
cannot be easily explained by a single dominant effect but instead often results from multiple, co-
occurring mechanisms that impair different steps along the cancer immunity cycle. 
 
4. Award for the best abstract  
Lastly, two selected abstracts from young researchers were presented.  
The existence of CSC represents a big threat for TNBC patient clinical outcome, given the CSC 
therapy-resistant capacity (Chang 2016). Therefore, the identification of therapeutic approaches 
that could lead to their eradication is of seminal importance for reducing tumor recurrence and 









Tatiana Volpari (Unit of Immunotherapy and Anticancer innovative Therapeutics, Fondazione 
IRCCS INT, Milan, Italy) presented novel data on the role of the transcriptional repressor BCL6 in 
regulating stemness features of TNBC stem cells. In particular, BCL6 overexpression was associated 
with a worse overall survival in TNBC patients. Moreover, GSEA results highlighted an enrichment 
in stemness signature genes in TNBC cases that overexpressed BCL6. Among the signaling 
pathways known to have a role in TNBC stemness, the NOTCH pathway showed a higher 
enrichment in patients with BCL6–TNBC, using an in silico approach. Volpari and colleagues 
therefore further investigated the role of BCL6 in TNBC stem cells in vitro, taking advantage of a 
highly potent and specific BCL6 inhibitor, the small molecule FX1, which is able to disrupt the 
recruitment of BCL6 co-repressors, thereby inhibiting BCL6’s repressive function on its target 
genes (Cardenas, Yu et al. 2016). The results obtained point to BCL6 as a key molecule in 
maintaining proliferation and self-renewal capacity of TNBC stem cells. Moreover, the molecular 
mechanisms supporting these evidences were investigated, and a novel BCL6 target gene was 
identified (manuscript in preparation).       
Lung cancer is the leading cause of cancer-related deaths due to late diagnosis and inadequate 
therapies (Siegel, Miller et al. 2018). MicroRNAs (miRNAs) are small non-coding RNAs that are de-
regulated in cancer and are involved in lung cancer development (Boeri, Pastorino et al. 2012). By 
targeting multiple transcripts, miRNAs epigenetically regulate fundamental cellular processes such 
as cell proliferation, apoptosis, differentiation, and migration, strongly indicating that they may 
function as potential oncogenes or tumor suppressors in cancer development (Iorio and Croce 
2012). Due to their ability to simultaneously regulate several cancer-related genes, they represent 
an interesting therapeutic approach for cancer treatment (Gandellini, Profumo et al. 2011). 
Orazio Fortunato (Fondazione IRCCS INT, Milan, Italy) and colleagues have previously 
demonstrated that miR-660 is downmodulated in plasma and tissues of lung cancer patients, and 
that re-introducing it reduced lung cancer growth by inhibiting the MDM2-P53 axis (Fortunato, 
Boeri et al. 2014). They have now developed coated cationic liposomes containing miR-660 mimic 
(CCL660) and tested their efficacy in established lung cancer PDX mouse models (Moro, Bertolini 
et al. 2017). Systemic delivery of liposomal miR-660 increased miRNA levels in tumors and 
significantly reduced tumor growth in two p53 wild-type PDXs without off-target effects. CCL660 
administration reduced the number of proliferating cancer cells by inhibiting MDM2 and restoring 
p53 function as well as that of its downstream effectors, such as p21. Interestingly, inhibition of 









CCL660 administration. Moreover, to assess the potential role of miR-660 in metastatic 
dissemination, H460 metastatic lung cancer cells overexpressing miR-660 were intravenously 
injected into SCID mice. Analysis with PET imaging showed a reduction of the formation of lung 
cancer nodules, which was confirmed by immunohistochemical analysis in H460-mir-660 cells, 
suggesting a potential role of mir-660 in the metastatic process. As miRNA accumulation in non-
target organs was also observed, a potential for toxic effects of both miRNAs and liposomes was 
questioned. However, in vitro assays demonstrated that miR-660 overexpression did not induce 
any changes in terms of proliferation or apoptosis in normal cells from either mouse or human. 
Notably, a phase 1 clinical trial using MRX34 in liver cancers has been halted due to multiple 
immune-related severe adverse events (Chakraborty, Sharma et al. 2017). To address this, 
Fortunato and colleagues have now analyzed immune infiltrates and pro-inflammatory cytokine 
release in immunocompetent mice after single or prolonged CCL660 administration. Interestingly, 
liposome entrapping synthetic miR-660 had no immunological off-target or acute/chronic toxic 
effects in immunocompetent mice. 
Altogether, these promising results offer a new boost for the development of miRNA-delivering 
compounds in the treatment of lung cancer that no longer induce immune-related toxic effects. 
 
6. Conclusions 
Cancer research is taking important steps forward towards understanding the molecular 
mechanisms involved in cancer development, maintenance, invasiveness, metastasis, and 
importantly, the mechanisms underlying anti-tumor therapy resistance. Tumors are no longer 
considered as merely “composed of cancer cells”; rather, the critical and regulatory role of the 
tumor microenvironment (TME), comprising stromal cells as well as the anti-tumor/pro-tumor 
immune system, is becoming increasingly clear. Novel therapeutic approaches should therefore 
take into account all these aspects to succeed in improving patient care.  
During the Ninth Edition of the Annual Congress on “Anticancer Innovative therapy”, experts in 
the field of immuno-oncology, epigenetics, tumor cell signaling, and cancer metabolism shared 
their latest knowledge acquired on the roles of i) epigenetics, and in particular, chromatin 
modifiers, ii) cancer metabolism, iii) cancer stem cells (CSCs), iv) tumor cell signaling, and iv) the 
immune system. The novel therapeutic approaches presented included epigenetic drugs, cell cycle 
inhibitors combined with ICB, antibiotics and other off-label drugs, small-molecules active against 









Moreover, important evidence on possible mechanisms of resistance to these innovative therapies 
were also discussed, in particular with respect to resistance to ICB.  
Overall, this conference provided scientists and clinicians with a broad overview of future 
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Figure 1. Immune-modulating effects of CDK4/6 inhibitors. CDK4/6 inhibitors exert their anti-
tumor effects not only by blocking cell division, but also by inducing the immune system. In 
particular, they enhance antigen presentation capacity of tumor cells and increase T-cell 
activation, leading to a synergistic effect with anti-PD-L1 therapy (from DA Schaer et al., 2018). 
 
 
Figure 2. High mitochondrial mass as a novel marker of chemo-resistant CSCs. Live MitoTracker 
staining could be exploited to discern CSCs with high (mito-high) and low (mito-low) mitochondrial 
mass. Considering the drug-resistant capacity of the mito-high subpopulation, a high 
mitochondrial mass can be considered a biomarker of chemo-resistant CSCs that can be easily 
isolated and subjected to drug screening. This approach could therefore represent a novel clinical 











Figure 3. Efficacy of CD30.CAR-Ts in lymphoma patients. Nine patients were infused with 
CD30.CAR-Ts, and their clinical responses were evaluated by PET. (A) CR, complete response; NR, 
no response; PR, partial response; SD, stable disease. (B) Six weeks after the first infusion of 
CD30.CAR-Ts, PET scans showed PR in patient #9, and CR was obtained after the fourth infusion 
for this patient. (C) CR was observed six weeks after the first infusion of CD30.CARTs also for 
patient #6, and confirmed 20 weeks later (from Ramos CA et al., 2017). 
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